The Strength study aim to evaluate the use of the RenalGuard device to protect the patients at high risk to develop acute kidney injury following a complex cardiovascular intervention requiring a high volume of contrast. ID: NCT02793661
The THRIVE study is a pivotal, prospective, multicenter, 2:1 randomized, double blind, controlled, study. The objective is to compare the THerapeutic IntravasculaR Ultrasound (TIVUS ) REnal Denervation System vs. Sham for the Adjunctive Treatment of Hypertension.
RADIUS-HTN study is a prospective, multi-center, international, post-market, randomized (1:1) clinical trial in patients with uncontrolled hypertension. The objective is to compare the safety and efficacy of radio frequency renal denervation using the Iberis Renal Denervation System (AngioCare) via...
EuroNetrod HTN OFF-Med Study is a multi-center blinded, 3-arm randomized (2:1:1) controlled investigation that aims to evaluate the efficacy and safety of the Netrod™ RDN system in patients with uncontrolled primary hypertension in the absence of antihypertensive medication, comparing the outcomes...
The goal of this feasibility study is to evaluate the safety and efficacy of the Renal Stimulation (RNS) by Direct Wire Pacing, during Renal Denervation (RDN) procedure in patient candidate for renal denervation with the ParadiseTM System. The main questions it aims to answer are: Is the RNS before...
RE-ADAPT-HF is a prospective, multicenter, randomized, blinded, sham-controlled, feasibility study of renal denervation in patients with chronic heart failure. Randomisation (1:1; Renal Denervation: Sham) of approximately 144 subjects (72 in each arm).
